BioNTech SE (BNTX) Announces 5M Share Proposed Public Offerings of ADSs and Rights Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BioNTech SE (BNTX) files to offer 5 Million ADSs and 750K for selling shareholders
July 21, 2020 8:27 AM EDTBioNTech SE (NASDAQ: BNTX) files to offer 5 Million ADSs and 750K for selling shareholders.
From the filing:
We are offering 5,000,000 American Depositary Shares,... More
BofA Securities Upgrades BioNTech (BNTX) to Buy as Positive Vaccine Updates Likely to Continue
July 21, 2020 4:19 AM EDT(Updated - July 21, 2020 6:53 AM EDT)
(updated to add analyst comments)
BofA Securities analyst Tazeen Ahmad upgraded BioNTech (NASDAQ: BNTX) from Neutral to Buy with a price target of $105 (from $71), saying the company's vaccine program with Pfizer is starting to differentiate... More
Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
July 20, 2020 8:46 AM EDTBioNTech SE (Nasdaq: BNTX) and Pfizer Inc. (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are... More
